A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
← catalyst calendarNCT07003425 · readout ≤ 1,229 d
Sponsored by Apogee Therapeutics, Inc. (industry) · APGE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · Quadruple · Treatment
Enrollment
350estimated
Sites
67
Countries
Canada, Czechia, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-14 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: APG777
- Drug: APG777
- Drug: APG777
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events
measured Up to 3 years
Permalink · APGE's whole pipeline · Catalyst calendar · Every registered study · What changed